Indoco Remedies Ltd - 532612 - Statement Of Investor Complaints For The Quarter Ended March 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- JAYSHANKAR MENONDesignation :- Company Secretary and Compliance Officer Indoco Remedies Ltd - 532612 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 
Indoco Remedies share price jumps 5% on launching Brinzolamide Ophthalmic Suspension in US
The ANDA approved by the US Food and Drug Administration (US FDA) for Brinzolamide Ophthalmic Suspension 1 percent, is used to treat high pressure inside the eye due to ocular hypertension and open-angle glaucoma, the company said. INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Indoco announces the launch of Brinzolamide Ophthalmic Suspension 1% in the US market by Teva Pharmaceuticals
Buy Indoco Remedies; target of Rs 358: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Indoco Remedies has recommended buy rating on the stock with a target price of Rs 358 in its research report dated February 10, 2021. INDOCO REMEDIES LTD. - 532612 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Publication of Quarterly Results
INDOCO REMEDIES LTD. - 532612 - Unaudited Financial Results
Unaudited financial results for the quarter ended 31.12.2020